Abstract

Natural product compounds have recently attracted significant attention from the scientific community for their potent effects against inflammation-driven diseases, including cancer. A significant amount of research, including preclinical, clinical, and epidemiological studies, has indicated that dietary consumption of polyphenols, found at high levels in cereals, pulses, vegetables, and fruits, may prevent the evolution of an array of diseases, including cancer. Cancer development is a carefully orchestrated progression where normal cells acquires mutations in their genetic makeup, which cause the cells to continuously grow, colonize, and metastasize to other organs such as the liver, lungs, colon, and brain. Compounds that modulate these oncogenic processes can be considered as potential anti-cancer agents that may ultimately make it to clinical application. Resveratrol, a natural stilbene and a non-flavonoid polyphenol, is a phytoestrogen that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. It has been reported that resveratrol can reverse multidrug resistance in cancer cells, and, when used in combination with clinically used drugs, it can sensitize cancer cells to standard chemotherapeutic agents. Several novel analogs of resveratrol have been developed with improved anti-cancer activity, bioavailability, and pharmacokinetic profile. The current focus of this review is resveratrol’s in vivo and in vitro effects in a variety of cancers, and intracellular molecular targets modulated by this polyphenol. This is also accompanied by a comprehensive update of the various clinical trials that have demonstrated it to be a promising therapeutic and chemopreventive agent.

Highlights

  • Cancer is one of the most commonly diagnosed diseases, and its related morbidity and mortality constitute a very significant health problem worldwide

  • With breast cancer cell–implanted fat-pad models employing cigarette smoke condensate–transformed Michigan cancer foundation (MCF)-10ATr cells [209] or SUM159 cells [253], resveratrol caused down-regulation of the expression of various proteins linked to survival and cell proliferation, proteins related to DNA repair (Fen-1, DNA-ligase-I, Pol-δ, and Pol-ε), and an anti-apoptotic protein (Bcl-xL)

  • Resveratrol considerably inhibited carcinoma development when it was injected in close proximity to the carcinoma in a tumor model created by transplanting human primary gastric cancer cells into the subcutaneous tissue of nude mice [297]

Read more

Summary

Introduction

Cancer is one of the most commonly diagnosed diseases, and its related morbidity and mortality constitute a very significant health problem worldwide. Revived interest in phytochemicals obtained from dietary or medicinal plant sources has provided an alternative source of bioactive compounds that can be used as preventive or therapeutic agents against a variety of diseases [19,20,21,22,23]. Phytochemicals such as phytoestrogens have been reported to modulate multiple cellular-signaling pathways, with no or minimal toxicity to normal cells [24,25].

In Vitro Pharmacological Properties and Anti-Cancer Effects of Resveratrol
Anti-Tumor-Promotion Activity
Anti-Tumor-Progression Activity
Pre-Clinical Studies
Skin Cancer
Breast Cancer
Prostate Cancer
10. Colorectal Cancer
11. Liver Cancer
12. Pancreatic Cancer
13. Lung Cancer
14. Other Cancers
15. Clinical Trials with Resveratrol
Participants
Findings
16. Conclusions and Future Perspectives

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.